Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 8/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17801583 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL4434918 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL22467822 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL17801581 | 1.00 | SCN9A (0.32) | SCN9ADPP4DPP7RORCSLC18A3 | |
| SCHEMBL1964520 | 0.85 | L3MBTL3 (0.31) | L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL2223995 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL288363 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL2221226 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL1444883 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 | |
| SCHEMBL2221215 | 0.83 | DPP4 (0.33) | SCN9ADPP4DPP7SLC18A3DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347580-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-111527091-B | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2023-03-28 | — | — | CN | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| WO-2022254362-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | NOVARTIS AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| EP-3733673-B1 | OXY-FLUOROPIPERIDINE DERIVATIVE AS KINASE INHIBITOR | DAE WOONG PHARMA (KR) | 2022-06-29 | — | — | EP | disclosed |
| US-11339167-B2 | Substituted piperidines as kinase inhibitors | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-05-24 | — | — | US | disclosed |
| EP-3733673-A1 | OXY-FLUOROPIPERIDINE DERIVATIVE AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-11-04 | — | — | EP | disclosed |
| US-20200308177-A1 | Oxy-fluoropiperidine Derivative as Kinase Inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-01 | — | — | US | disclosed |
| CN-111527091-A | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2020-08-11 | — | — | CN | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | SCN9A 4610/4885DPP4 236/4885DPP7 57/4885 |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | SCN9A 1932/4885DPP4 4439/4885DPP7 3629/4885 |
| US-11339167-B2 | Substituted piperidines as kinase inhibitors | CNKSR1, MAP4K5, MAP3K1 | SCN9A 2123/4885DPP4 1586/4885DPP7 1339/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | SCN9A 4610/4885DPP4 236/4885DPP7 57/4885 |
| US-20200308177-A1 | Oxy-fluoropiperidine Derivative as Kinase Inhibitor | MAP3K1, MAP3K6, MAP3K2 | SCN9A 2415/4885DPP4 3097/4885DPP7 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.